SCHEMBL201365

SCHEMBL201365

NC(=O)c1cc(O)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 1/20 0.47
DYRK1A Q13627 1/20 0.47
DYRK1B Q9Y463 1/20 0.47
DGAT1 O75907 1/20 0.47
HSD17B1 P14061 2/20 0.45
HSD17B2 P37059 2/20 0.45
CA12 O43570 3/20 0.43
CA1 P00915 3/20 0.43
CA2 P00918 3/20 0.43
CA7 P43166 3/20 0.43
CA9 Q16790 3/20 0.43
CA14 Q9ULX7 3/20 0.43
CES2 O00748 2/20 0.43
ALOX5 P09917 1/20 0.43
PTGS2 P35354 1/20 0.43
CES1 P23141 1/20 0.43
LCK P06239 1/20 0.42
PARP1 P09874 1/20 0.42
CHRNA7 P36544 1/20 0.41
MAP2K2 P36507 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1055849 0.83 DGAT1 (0.62) DGAT1CA12CA1CA2CA7
SCHEMBL29537903 0.80 CES2 (0.68) DGAT1CA9CA14CES2CES1
SCHEMBL1264408 0.80 CA1 (0.61) CLK1DYRK1ADYRK1BHSD17B1HSD17B2
SCHEMBL366058 0.80 CES2 (0.68) DGAT1CA9CA14CES2CES1
SCHEMBL1805264 0.79 CES2 (0.50) DGAT1CA12CA1CA2CA7
SCHEMBL3086810 0.78 PARP1 (0.50) DGAT1CES2CES1LCKPARP1
SCHEMBL910922 0.78 ALDH1A1 (0.56) DGAT1CA1CA2CES2CES1
SCHEMBL30564933 0.78 ALDH1A1 (0.56) DGAT1CA1CA2CES2CES1
SCHEMBL28248515 0.78 ALDH1A1 (0.54) CLK1DYRK1ADYRK1BHSD17B1HSD17B2
SCHEMBL13100129 0.78 CLK1 (0.47) CLK1DYRK1ADYRK1BHSD17B1HSD17B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4709716-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 EP disclosed
US-20250179008-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. (US) 2025-06-05 US disclosed
WO-2024233554-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2024-11-14 WO disclosed
CN-117024368-A Dimethoimidazole derivative and application thereof 中国人民解放军海军军医大学 2023-11-10 CN disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-20150191420-A1 ANTIBACTERIAL AGENTS TAXIS PHARMACEUTICALS, INC. 2015-07-09 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
US-8865736-B2 Antibacterial agents Biota Scientific Pty Ltd (AU) 2014-10-21 US disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
EP-1996180-B1 BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS BIOTA EUROPE LTD (GB) 2011-08-03 EP disclosed
CN-102008459-A Antibacterial agents PROLYSIS LTD 2011-04-13 CN disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
US-20100173933-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2010-07-08 US disclosed
CN-101404989-A Antibacterial agent PROLYSIS LTD (GB) 2009-04-08 CN disclosed
EP-1996180-A1 ANTIBACTERIAL AGENTS Prolysis Limited (GB) 2008-12-03 EP disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed
WO-2007107758-A1 ANTIBACTERIAL AGENTS PROLYSIS LTD (GB) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150191420-A1 ANTIBACTERIAL AGENTS ALK, ARG1, ROS1 CLK1 4643/4885DYRK1A 3576/4885DYRK1B 3748/4885
US-20250179008-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 CLK1 4344/4885DYRK1A 4146/4885DYRK1B 4247/4885
US-20100173933-A1 ANTIBACTERIAL AGENTS ALK, ROS1, NOX1 CLK1 4344/4885DYRK1A 4146/4885DYRK1B 4247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.